Creating a diagnostic model for renal cell carcinoma with tumor thrombus invasion

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a preoperative imaging diagnostic model that aligns closely with histopathological examinations for renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus. It will evaluate the impact of different layers of vascular wall invasion on long-term prognosis and identify which layers of invasion are clinically significant for treatment decisions. Patients diagnosed with RCC and IVC tumor thrombus will be included and categorized based on their vascular wall invasion status, allowing for a systematic approach to understanding the disease's progression and treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults ≥18 years of age;
* Accepted abdominal ultrasonography, contrast-induced ultrasonography, enhanced CT and MRI before the surgery;
* Diagnosis of primary renal cell carcinoma with tumor thrombus before and during the surgery;
* Received radical nephrectomy and at least one kind of thrombectomy (including IVC incision only, IVC partial resection, IVC diagonal resection, and IVC segmental resection)
* Can tolerate the surgery;
* Eastern Cooperative Oncology Group Performance Status Scale (ECOG-PS) 0\~2;
* No previous history of malignant tumor;
* Willing to return for required follow-up visits

Exclusion Criteria:

* Failed to receive standard nephrectomy for any reason;
* Attached other addition operations in the surgery;
* Received neoadjuvant treatment before the surgery;
* Experience any other conditions that may affect the curative effect (e.g. active tuberculosis, autoimmune disease, or oral glucocorticoids treatment);
* Experience serious consequences or death due to anesthesia accident during operation;

Where it's running

• Peking University Third Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Jiyuan Chen, MD
• Email: 1910301319@pku.edu.cn
• Phone: +86 18801430995

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Belzutifan plus zanzalintinib versus belzutifan alone for advanced renal cell carcinoma

  This trial tests whether adding the targeted drug zanzalintinib to belzutifan helps people with advanced renal cell carcinoma live longer and delay tumor growth compared with belzutifan plus placebo.

  Recruiting at 107 sites Phase 3 Merck Sharp & Dohme LLC · Duarte, California and 110 other locations · NCT07489495

• PF-08634404 alone and with other anticancer medicines for adults with advanced kidney cancer.

  This tests whether PF-08634404, given alone or with other cancer medicines, is safe and helps adults with locally advanced or metastatic kidney cancer who have not had prior systemic treatment.

  Recruiting at 157 sites Phase 1/2 Pfizer · Phoenix, Arizona and 182 other locations · NCT07227415

• Deep-learning tool to distinguish T1–T2 from T3 renal cell carcinoma on contrast-enhanced CT.

  This project will see if a computer model can tell whether kidney cancer is early (T1–T2) or locally advanced (T3) using contrast-enhanced CT scans before surgery.

  Recruiting Peking University First Hospital · Beijing · NCT07166445

• A kidney cancer prediction model to guide treatment decisions, including for patients with tumor thrombus

  This project will test whether a new prediction model can guide treatment choices to improve survival for adults with renal cell carcinoma, including those with venous tumor thrombus.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07117227

• Using vorolanib for treating advanced kidney cancer

  This study is testing if the drug vorolanib can help people with advanced kidney cancer live longer when used as a second treatment option.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT06676527

• Evaluating bicalutamide and sunitinib for advanced kidney cancer

  This study is testing if a combination of two medications, bicalutamide and sunitinib, can help people with advanced kidney cancer who have not responded to previous treatments.

  Recruiting Phase 1/2 State University of New York at Buffalo · Buffalo, New York · NCT06222593

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.